Figure 5

Transgenic expression of CSF-1 does not improve the protection against BCG in NSG-BLT mice. NSG-BLT and NSG-CSF1-BLT mice were generated as described in the Methods section. At 16 weeks spleens from NSG-CSF1-BLT mice were recovered and tested for human cell engraftment (A) and human macrophage development (B and C). Human macrophage were defined as CD14⁺/CD33⁺ and the (B) percentage and (C) number of positive cells are shown. NSG-CSF1 and NSG-CSF1-BLT mice were infected with BCG and bacterial loads in the lung (D) and spleen (E) were measured by CFU assay (D). N = 4 for NSG-CSF1 and NSG-CSF1-BLT mice. *p < 0.05.